Health Care [ 9/12 ] | Pharmaceuticals [ 21/73 ]
NASDAQ | Common Stock
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 3 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial.
The company's products also consists ARV 393, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes which is in Phase 1 first-in-human clinical trial; ARV 102 for the treatment of neurodegenerative diseases, which is in Phase 1 clinical trial; and KRAS G12D program is in preclinical development for pancreatic and colorectal cancers.
Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F.
Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG.
The company was founded in 2013 and is based in New Haven, Connecticut.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 1, 25 | 1.14 Increased by +217.53% | -0.97 Increased by +217.56% |
| Feb 25, 25 | -0.63 Increased by +75.10% | -0.96 Increased by +34.29% |
| Oct 30, 24 | -0.68 Increased by +42.37% | -0.96 Increased by +29.17% |
| Jul 30, 24 | -0.49 Increased by +60.80% | -0.86 Increased by +43.02% |
| May 7, 24 | -0.97 Increased by +37.01% | -1.42 Increased by +31.69% |
| Feb 27, 24 | -2.53 Decreased by -62.18% | -1.27 Decreased by -99.21% |
| Nov 7, 23 | -1.18 Increased by +4.84% | -1.58 Increased by +25.32% |
| Aug 8, 23 | -1.25 Increased by +5.30% | -1.65 Increased by +24.24% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 188.80 M Increased by +646.25% | 82.90 M Increased by +219.45% | Increased by +43.91% Increased by +116.01% |
| Dec 31, 24 | 59.20 M Increased by +237.35% | -45.10 M Increased by +70.87% | Decreased by -76.18% Decreased by -121.21% |
| Sep 30, 24 | 102.40 M Increased by +195.95% | -49.20 M Increased by +23.13% | Decreased by -48.05% Increased by +74.02% |
| Jun 30, 24 | 76.50 M Increased by +40.37% | -35.20 M Increased by +47.15% | Decreased by -46.01% Increased by +62.35% |
| Mar 31, 24 | 25.30 M Decreased by -22.15% | -69.40 M Increased by +14.11% | Decreased by -274.31% Decreased by -10.33% |
| Dec 31, 23 | -43.10 M Decreased by -213.42% | -154.80 M Decreased by -93.74% | Increased by +359.16% Increased by +270.82% |
| Sep 30, 23 | 34.60 M Increased by +14.19% | -64.00 M Increased by +3.32% | Decreased by -184.97% Increased by +15.34% |
| Jun 30, 23 | 54.50 M Increased by +74.12% | -66.60 M Increased by +4.86% | Decreased by -122.20% Increased by +45.36% |